Neurotrophins and their receptors in breast cancer

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 357-365

  Hondermarck, Hubert ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Biomarkers; Breast cancer; Neurotrophins; Therapeutic targets; Tumor growth and metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; AZ 23; AZD 6918; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CEP 2563; CEP 751; ENDOCANNABINOID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GNF 5837; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KU ANTIGEN; LESTAURTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NEUROTROPHIN; NEUROTROPHIN 4; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE PHOSPHATASE SHP 1; TAMOXIFEN; TANEZUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER INVASION; CANCER PAIN; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; HUMAN; IMMUNOCOMPETENT CELL; METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; NERVE GROWTH FACTORS; RECEPTORS, NERVE GROWTH FACTOR;

EID: 84869884311     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.06.004     Document Type: Short Survey

References (105)

1. Lin S.X., Chen J., Mazumdar M., Poirier D., Wang C., Azzi A., et al. Molecular therapy of breast cancer: progress and future directions. Nature Reviews Endocrinology 2010, 6:485-493.
2. Higgins M.J., Baselga J. Targeted therapies for breast cancer. Journal of Clinical Investigation 2011, 121:3797-3803.
3. Lann D., LeRoith D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2008, 13:371-379.
4. Hynes N.E., Dey J.H. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Research 2010, 70:5199-5202.
5. Heinzle C., Sutterlüty H., Grusch M., Grasl-Kraupp B., Berger W., Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opinion on Therapeutic Targets 2011, 15:829-846.
6. Chang H.R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010, 116:2856-2867.
7. Mathew J., Perez E.A. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Current Opinion in Oncology 2011, 23:594-600.
8. Hondermarck H., Tastet C., El Yazidi-Belkoura I., Toillon R.A., Le Bourhis X. Proteomics of breast cancer: the quest for markers and therapeutic targets. Journal of Proteome Research 2008, 7:1403-1411.
9. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
10. Bertos N.R., Park M. Breast cancer - one term, many entities?. Journal of Clinical Investigation 2011, 121:3789-3796.
11. Di Cosimo S., Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. Nature Reviews Clinical Oncology 2010, 7:139-147.
12. Skaper S.D. The neurotrophin family of neurotrophic factors: an overview. Methods in Molecular Biology 2012, 846:1-12.
13. Hallböök F., Wilson K., Thorndyke M., Olinski R.P. Formation and evolution of the chordate neurotrophin and Trk receptor genes. Brain, Behavior and Evolution 2006, 68:133-144.
14. Teng K.K., Felice S., Kim T., Hempstead B.L. Understanding proneurotrophin actions: recent advances and challenges. Developmental Neurobiology 2010, 70:350-359.
15. Schecterson L.C., Bothwell M. Neurotrophin receptors: old friends with new partners. Developmental Neurobiology 2010, 70:332-338.
16. Nykjaer A., Willnow T.E. Sortilin: a receptor to regulate neuronal viability and function. Trends in Neurosciences 2012, 35:261-270.
17. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2006, 361:1545-1564.
18. Descamps S., Lebourhis X., Delehedde M., Boilly B., Hondermarck H. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. Journal of Biological Chemistry 1998, 273:16659-16662.
19. Descamps S., Toillon R.A., Adriaenssens E., Pawlowski V., Cool S.M., Nurcombe V., et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. Journal of Biological Chemistry 2001, 276:17864-17870.
20. El Yazidi-Belkoura I., Adriaenssens E., Dollé L., Descamps S., Hondermarck H. Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells. Journal of Biological Chemistry 2003, 278:16952-16956.
21. Dollé L., El Yazidi-Belkoura I., Adriaenssens E., Nurcombe V., Hondermarck H. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003, 22:5592-5601.
22. Tagliabue E., Castiglioni F., Ghirelli C., Modugno M., Asnaghi L., Somenzi G., et al. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. Journal of Biological Chemistry 2000, 275:5388-5394.
23. Melck D., De Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M., et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000, 141:118-126.
24. Chiarenza A., Lazarovici P., Lempereur L., Cantarella G., Bianchi A., Bernardini R. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Research 2001, 61:3002-3008.
25. Descamps S., Pawlowski V., Revillion F., Hornez L., Hebbar M., Boilly B., et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Research 2001, 61:4337-4340.
26. Aragona M., Panetta S., Silipigni A.M., Romeo D.L., Pastura G., Mesiti M., et al. Nerve growth factor receptor immunoreactivity in breast cancer patients. Cancer Investigation 2001, 19:692-697.
27. Adriaenssens E., Vanhecke E., Saule P., Mougel A., Page A., Romon R., et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Research 2008, 68:346-351.
28. Davidson B., Reich R., Lazarovici P., Ann Florenes V., Nielsen S., Nesland J.M. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Research and Treatment 2004, 83:119-128.
29. Lagadec C., Meignan S., Adriaenssens E., Foveau B., Vanhecke E., Romon R., et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009, 28:1960-1970.
30. Com E., Lagadec C., Page A., El Yazidi-Belkoura I., Slomianny C., Spencer A., et al. Nerve growth factor receptor TrkA signaling in breast cancer cells involves Ku70 to prevent apoptosis. Molecular and Cellular Proteomics 2007, 6:1842-1854.
31. Lagadec C., Romon R., Tastet C., Meignan S., Com E., Page A., et al. Ku86 is important for TrkA overexpression-induced breast cancer cell invasion. Proteomics - Clinical Applications 2010, 4:580-590.
32. Montano X. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation. Oncogene 2009, 28:3787-3800.
33. Naderi A., Teschendorff A.E., Beigel J., Cariati M., Ellis I.O., Brenton J.D., et al. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Research 2007, 67:6725-6736.
34. Naderi A., Hughes-Davies L. Nerve growth factor/nuclear factor-kappaB pathway as a therapeutic target in breast cancer. Journal of Cancer Research and Clinical Oncology 2009, 135:211-216.
35. Verbeke S., Meignan S., Lagadec C., Germain E., Hondermarck H., Adriaenssens E., et al. Overexpression of p75(NTR) increases survival of breast cancer cells through p21(waf1). Cellular Signalling 2010, 22:1864-1873.
36. Thiele C.J., Li Z., McKee A.E. On Trk - the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clinical Cancer Research 2009, 15:5962-5967.
37. Roesler R., de Farias C.B., Abujamra A.L., Brunetto A.L., Schwartsmann G. BDNF/TrkB signaling as an anti-tumor target. Expert Review of Anticancer Therapy 2011, 11:1473-1475.
38. Cameron H.L., Foster W.G. Dieldrin promotes resistance to anoikis in breast cancer cells in vitro. Reproductive Toxicology 2008, 25:256-262.
39. Cameron H.L., Foster W.G. Developmental and lactational exposure to dieldrin alters mammary tumorigenesis in Her2/neu transgenic mice. PLoS One 2009, 4:e4303.
40. Vanhecke E., Adriaenssens E., Verbeke S., Meignan S., Germain E., Berteaux N., et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clinical Cancer Research 2011, 17:1741-1752.
41. Patani N., Jiang W.G., Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell International 2011, 11:23.
42. Tozlu S., Girault I., Vacher S., Vendrell J., Andrieu C., Spyratos F., et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine-Related Cancer 2006, 13:1109-1120.
43. Fenner B.M. Truncated TrkB: beyond a dominant negative receptor. Cytokine and Growth Factor Reviews 2012, 23:15-24.
44. Howe E.N., Cochrane D.R., Richer J.K. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Research 2011, 13:R45.
45. Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S., et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004, 427:843-848.
46. Truzzi F., Marconi A., Lotti R., Dallaglio K., French L.E., Hempstead B.L., et al. Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. Journal of Investigative Dermatology 2008, 128:2031-2040.
47. Demont Y., Corbet C., Page A., Ataman-önal Y., Choquet-Kastylevsky G., Fliniaux I., et al. Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. Journal of Biological Chemistry 2012, 287:1923-1931.
48. Jin W., Yun C., Jeong J., Park Y., Lee H.D., Kim S.J. c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Journal of Biological Chemistry 2008, 283(3):1391-1400.
49. Jin W., Kim G.M., Kim M.S., Lim M.H., Yun C., Jeong J., et al. TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 2010, 31:1939-1947.
50. Blasco-Gutiérrez M.J., José-Crespo I.J., Zozaya-Alvarez E., Ramos-Sánchez R., García-Atarés N. TrkC: a new predictive marker in breast cancer?. Cancer Investigation 2007, 25:405-410.
51. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genetics 2005, 37:590-592.
52. Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutation 2006, 27:1060-1061.
53. Nikoletopoulou V., Lickert H., Frade J.M., Rencurel C., Giallonardo P., Zhang L., et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 2010, 467:59-63.
54. Bouzas-Rodriguez J., Cabrera J.R., Delloye-Bourgeois C., Ichim G., Delcros J.G., Raquin M.A., et al. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. Journal of Clinical Investigation 2010, 120:850-858.
55. Tauszig-Delamasure S., Bouzas-Rodriguez J. Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy. Expert Opinion on Therapeutic Targets 2011, 15:847-858.
56. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Research 2012, 72(10):2473-2480.
57. Place A.E., Jin Huh S., Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Research 2011, 13:227.
58. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
59. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation 2011, 121:3804-3809.
60. Le Bourhis X., Romon R., Hondermarck H. Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications. Breast Cancer Research and Treatment 2010, 120:17-24.
61. Waldner M.J., Neurath M.F. Targeting the VEGF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012, 16:5-13.
62. Cantarella G., Lempereur L., Presta M., Ribatti D., Lombardo G., Lazarovici P., et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB Journal 2002, 16:1307-1309.
63. Emanueli C., Salis M.B., Pinna A., Graiani G., Manni L., Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 2002, 106:2257-2262.
64. Park M.J., Kwak H.J., Lee H.C., Yoo D.H., Park I.C., Kim M.S., et al. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. Journal of Biological Chemistry 2007, 282:30485-30496.
65. Romon R., Adriaenssens E., Lagadec C., Germain E., Hondermarck H., Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Molecular Cancer 2010, 9:157.
66. Voss M.J., Möller M.F., Powe D.G., Niggemann B., Zänker K.S., Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer 2011, 11:158.
67. Koutras A.K., Fountzilas G., Makatsoris T., Peroukides S., Kalofonos H.P. Bevacizumab in the treatment of breast cancer. Cancer Treatment Reviews 2010, 36:75-82.
68. Guidolin D. The multifaceted world of angiogenesis control. Expert Opinion on Therapeutic Targets 2010, 14:1135-1138.
69. Kermani P., Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends in Cardiovascular Medicine 2007, 17:140-143.
70. Lam C.T., Yang Z.F., Lau C.K., Tam K.H., Fan S.T., Poon R.T. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma. Clinical Cancer Research 2011, 17:3123-3133.
71. Mantovani A. Molecular pathways linking inflammation and cancer. Current Molecular Medicine 2010, 10:369-373.
72. Nicolini A., Carpi A., Rossi G. Cytokines in breast cancer. Cytokine and Growth Factor Reviews 2006, 17:325-337.
73. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine and Growth Factor Reviews 2010, 21:27-39.
74. Kobayashi H., Gleich G.J., Butterfield J.H., Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 2002, 99:2214-2220.
75. Leon A., Buriani A., Dal Toso R., Fabris M., Romanello S., Aloe L., et al. Mast cells synthesize, store, and release nerve growth factor. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:3739-3743.
76. Nilsson G., Forsberg-Nilsson K., Xiang Z., Hallböök F., Nilsson K., Metcalfe D.D. Human mast cells express functional TrkA and are a source of nerve growth factor. European Journal of Immunology 1997, 27:2295-2301.
77. Santambrogio L., Benedetti M., Chao M.V., Muzaffar R., Kulig K., Gabellini N., et al. Nerve growth factor production by lymphocytes. Journal of Immunology 1994, 153:4488-4495.
78. Laoui D., Movahedi K., Van Overmeire E., Van den Bossche J., Schouppe E., Mommer C., et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology 2011, 55:861-867.
79. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research 1996, 56:4625-4629.
80. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Research 2007, 67:5064-5066.
81. Ley S., Weigert A., Weichand B., Henke N., Mille-Baker B., Janssen R.A., et al. The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. Oncogene 2012 March 12, [Epub ahead of print].
82. Vona-Davis L., Rose D.P. Angiogenesis, adipokines and breast cancer. Cytokine and Growth Factor Reviews 2009, 20:193-201.
83. Liebig C., Ayala G., Wilks J.A., Berger D.H., Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009, 115:3379-3391.
84. Marchesi F., Piemonti L., Mantovani A., Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine and Growth Factor Reviews 2010, 21:77-82.
85. Bapat A.A., Hostetter G., Von Hoff D.D., Han H. Perineural invasion and associated pain in pancreatic cancer. Nature Reviews Cancer 2011, 11:695-707.
86. Karak S.G., Quatrano N., Buckley J., Ricci A. Prevalence and significance of perineural invasion in invasive breast carcinoma. Connecticut Medicine 2010, 74:17-21.
87. Hoffman E.M., Zhang Z., Anderson M.B., Schechter R., Miller K.E. Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation. Neuroscience 2011, 193:452-465.
88. Mehlen P., Delloye-Bourgeois C., Chédotal A. Novel roles for slits and netrins: axon guidance cues as anticancer targets?. Nature Reviews Cancer 2011, 11:188-197.
89. Pezet S., McMahon S.B. Neurotrophins: mediators and modulators of pain. Annual Review of Neuroscience 2006, 29:507-538.
90. Schmidt B.L., Hamamoto D.T., Simone D.A., Wilcox G.L. Mechanism of cancer pain. Molecular Interventions 2010, 10:164-178.
91. Halvorson K.G., Kubota K., Sevcik M.A., Lindsay T.H., Sotillo J.E., Ghilardi J.R., et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Research 2005, 65:9426-9435.
92. Bloom A.P., Jimenez-Andrade J.M., Taylor R.N., Castañeda-Corral G., Kaczmarska M.J., Freeman K.T., et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. Journal of Pain 2011, 12:698-711.
93. George D.J., Suzuki H., Bova G.S., Isaacs J.T. Mutational analysis of the TrkA gene in prostate cancer. Prostate 1998, 36:172-180.
94. Harada T., Yatabe Y., Takeshita M., Koga T., Yano T., Wang Y., et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clinical Cancer Research 2011, 17:2638-2645.
95. Geiger T.R., Song J.Y., Rosado A., Peeper D.S. Functional characterization of human cancer-derived TRKB mutations. PLoS One 2011, 6(2):e16871.
96. Jimenez-Andrade J.M., Ghilardi J.R., Castañeda-Corral G., Kuskowski M.A., Mantyh P.W. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 2011, 152:2564-2574.
97. Garber K. Fate of novel painkiller mAbs hangs in balance. Nature Biotechnology 2011, 29:173-174.
98. Wang T., Yu D., Lamb M.L. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opinion on Therapeutic Targets 2009, 19:305-319.
99. Thress K., Macintyre T., Wang H., Whitston D., Liu Z.Y., Hoffmann E., et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Molecular Cancer Therapeutics 2009, 8:1818-1827.
100. Martin K.J., Shpiro N., Traynor R., Elliott M., Arthur J.S. Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays. Neuropharmacology 2011, 61:148-155.
101. Marshall J.L., Kindler H., Deeken J., Bhargava P., Vogelzang N.J., Rizvi N., et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Investigational New Drugs 2005, 23:31-37.
102. Chan E., Mulkerin D., Rothenberg M., Holen K.D., Lockhart A.C., Thomas J., et al. A phase I trial of CEP-701+gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs 2008, 26:241-247.
103. Hong S., Kim J., Seo J.H., Jung K.H., Hong S.S., Hong S. Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as trk inhibitors with anticancer and antiangiogenic activities. Journal of Medicinal Chemistry 2012, 55:5337-5349.
104. Albaugh P., Fan Y., Mi Y., Sun F., Adrian F., Li N., et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Medicinal Chemistry Letters 2012, 3:140-145.
105. Shiu K.K., Tan D.S., Reis-Filho J.S. Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opinion on Therapeutic Targets 2008, 12:1123-1137.